Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Regnase-1 is a rapid-response ribonuclease and RNA-binding protein (RBP) that plays a central role in post-transcriptional regulation of gene expression, particularly within the immune system. It promotes mRNA decay through its endoribonuclease activity, specifically targeting stem-loop structures within the 3′ untranslated regions (UTRs) of target mRNAs. It acts as a master regulator for cellular adaptation to microenvironmental changes by restricting inflammation and maintaining immune homeostasis. Its expression is rapidly induced under conditions such as microbial infection, exposure to inflammatory cytokines, or chemical/mechanical stimulation. Dysfunction or loss of Regnase‑1 results in enhanced inflammation and autoimmune pathology, while pharmacological modulation presents therapeutic opportunities for treating inflammatory diseases and certain cancers.
Inhibition of Regnase-1 activity promotes inflammation and lymphocyte activation. Modulation/activation of Regnase-1 may be a therapeutic strategy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Regnase-1 (N/A).